Skip to content

Effect of early combination of terlipressin and norepinephrine in the treatment of septic shock

Effect of early combination of terlipressin and norepinephrine in the treatment of septic shock

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082897
Enrollment
Unknown
Registered
2024-04-10
Start date
2022-02-09
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septic shock

Interventions

low-dose group:the dosage of norepinephrine exceeded 0.25 µg/(kg·min)
medium-dose group:the dosage of norepinephrine exceeding 0.5 µg/(kg·min)
high-dose group:when the dosage of norepinephrine exceeded 0.75 µg/(kg·min)

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) with sepsis, 2) needing vasoactive drugs to maintain MAP = 65 mmHg after full volume resuscitation (30 mL/kg of crystal solution within 3 h), 3) survival time is greater than 48 hours, and 4) with blood lactate concentration > 2 mmol/L.

Exclusion criteria

Exclusion criteria: 1) age < 18 years, 2) left ventricular dysfunction, 3) unstable coronary syndrome or acute myocardial infarction, 4) noticeable valvular heart disease, 5) mesenteric artery ischemia or vasospasm disease, 6) chronic renal failure, 7) pregnancy, 8) organ transplantation, 9) Raynaud’s phenomenon, 10) related drug allergy,11) previous use of TP.

Design outcomes

Primary

MeasureTime frame
the change of norepinephrine dosage;

Secondary

MeasureTime frame
adverse event;Blood pressure;serum lactate level;CRRT time;

Countries

China

Contacts

Public ContactZhenxing Ding

The First Affiliated Hospital of Anhui Medical University

dingdoctorzx@163.com+86 139 0969 4760

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026